LIGAND PHARMACEUTICALS INCORPORATED Impairment of Intangible Assets (Excluding Goodwill)
LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) reported Impairment of Intangible Assets (Excluding Goodwill) of $6.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-02-27
- LIGAND PHARMACEUTICALS INCORPORATED impairment of intangible assets (excluding goodwill) for the quarter ending 2025-12-31 was $6.20M, a 51.85% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED impairment of intangible assets (excluding goodwill) for the quarter ending 2025-09-30 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED impairment of intangible assets (excluding goodwill) for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED impairment of intangible assets (excluding goodwill) for the quarter ending 2025-03-31 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED impairment of intangible assets (excluding goodwill) for fiscal 2025 was $6.20M, a 79.73% decline from fiscal 2024.
- LIGAND PHARMACEUTICALS INCORPORATED impairment of intangible assets (excluding goodwill) for fiscal 2024 was $30.57M.
- LIGAND PHARMACEUTICALS INCORPORATED impairment of intangible assets (excluding goodwill) for fiscal 2023 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED impairment of intangible assets (excluding goodwill) for fiscal 2022 was $0.00.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $6.20M derived: sum of 2 quarters · filed 2026-02-27 | $6.20M derived: sum of 3 quarters · filed 2026-02-27 | $6.20M 10-K · filed 2026-02-27 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | $4.08M derived: sum of 4 quarters · filed 2026-02-27 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-08 | $0.00 10-Q · filed 2025-08-08 | $4.08M derived: sum of 3 quarters · filed 2026-02-27 | $4.08M derived: sum of 4 quarters · filed 2026-02-27 |
| 2025-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-02-27 | $4.08M derived: sum of 2 quarters · filed 2026-02-27 | $4.08M derived: sum of 3 quarters · filed 2026-02-27 | $30.57M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-12-31 | $4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $4.08M derived: sum of 2 quarters · filed 2026-02-27 | $30.57M derived: sum of 3 quarters · filed 2026-02-27 | $30.57M 10-K · filed 2026-02-27 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-07 | $26.49M derived: sum of 2 quarters · filed 2025-11-07 | $26.49M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $26.49M 10-Q · filed 2025-08-08 | $26.49M 10-Q · filed 2025-08-08 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-08 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 | |||
| 2010-12-31 | $2.80M 10-K · filed 2013-03-14 |